StreetInsider.com News Articles

Form 6-K Zhengye Biotechnology For: Aug 06

Thu, 06 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260806/26883940.html

Form 6-K Zhengye Biotechnology For: Aug 06

Thu, 06 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260806/26883940.html

Zhengye Biotechnology regains Nasdaq minimum bid price compliance

Thu, 06 Aug 2026 08:00:36 -0400

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) announced that it received a compliance letter from Nasdaq on August 5, 2026, confirming the company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

The company had previously received a deficiency notice from Nasdaq on May 29, 2026, stating that the closing bid price of its Class A ordinary shares had fallen below $1.00 per share for 30 consecutive business days. Nasdaq determined that the closing bid price remained at or above $1.00 per share for 10 consecutive business days, from July 20, 2026 through August 4, 2026, satisfying

Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement

Thu, 06 Aug 2026 08:00:00 -0400

Jilin, China, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that on August 5, 2026, the Company received a letter (the “Compliance Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2).

As previously disclosed, on May 29, 2026, the Company received

Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement

Thu, 06 Aug 2026 08:00:00 -0400

As previously disclosed, on May 29, 2026, the Company received

Form 6-K Zhengye Biotechnology For: Jul 21

Tue, 21 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260721/26795701.html

Form 6-K Zhengye Biotechnology For: Jul 21

Tue, 21 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260721/26795701.html

Zhengye Biotechnology unaware of cause for unusual trading activity

Tue, 21 Jul 2026 08:31:08 -0400

Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT), a China-based veterinary vaccine manufacturer, stated it is not aware of any material non-public information that would explain recent unusual activity in the price and trading volume of its Class A ordinary shares.

According to a statement issued July 21, 2026, the company said its business operations continue in the ordinary course and that there have been no undisclosed corporate developments, transactions, or events that management believes would account for the recent price or volume movements.

The company said it has been in contact with Nasdaq regarding the increase in trading volume and will continue to

Zhengye Biotechnology unaware of cause for unusual trading activity

Tue, 21 Jul 2026 08:31:08 -0400

The company said it has been in contact with Nasdaq regarding the increase in trading volume and will continue to

Zhengye Biotechnology unaware of cause for unusual trading activity

Tue, 21 Jul 2026 08:31:08 -0400

The company said it has been in contact with Nasdaq regarding the increase in trading volume and will continue to

Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity

Tue, 21 Jul 2026 08:30:00 -0400

Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today issued the following statement in response to recent unusual trading activity in the price and trading volume of its Class A ordinary shares.

The Company does not normally comment on market activity or rumors. However, in light of the magnitude of the recent trading activity in the Company's securities, the Company is providing the

Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity

Tue, 21 Jul 2026 08:30:00 -0400

The Company does not normally comment on market activity or rumors. However, in light of the magnitude of the recent trading activity in the Company's securities, the Company is providing the

Form 3 Zhengye Biotechnology For: Jun 25 Filed by: Han Zhenfa

Thu, 25 Jun 2026 11:42:00 -0400

si-local-file:///var/storage/secattach/20260625/26690276.html

Form 3 Zhengye Biotechnology For: Jun 25 Filed by: Cheng Yuhong (nmn)

Thu, 25 Jun 2026 11:41:00 -0400

si-local-file:///var/storage/secattach/20260625/26690268.html

Form 3 Zhengye Biotechnology For: Jun 25 Filed by: Song Songlin

Thu, 25 Jun 2026 11:40:00 -0400

si-local-file:///var/storage/secattach/20260625/26690259.html

Form 3 Zhengye Biotechnology For: Jun 25 Filed by: Jiang Ping (PiJi)

Thu, 25 Jun 2026 11:39:00 -0400

si-local-file:///var/storage/secattach/20260625/26690242.html

Form 3 Zhengye Biotechnology For: Jun 25 Filed by: Wang Ping (nmn)

Thu, 25 Jun 2026 11:39:00 -0400

si-local-file:///var/storage/secattach/20260625/26690251.html

Zhengye Biotechnology receives nasdaq deficiency notice

Thu, 04 Jun 2026 16:05:15 -0400

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT) received a notification from Nasdaq on May 29 stating the company does not meet the minimum bid price requirement for continued listing.

The veterinary vaccine manufacturer's shares failed to maintain the required $1.00 minimum bid price for 30 consecutive business days from April 16 to May 28, according to the notification letter. Nasdaq Listing Rule 5550(a)(2) mandates listed securities maintain this minimum threshold.

The notification does not immediately impact the company's listing on the Nasdaq Capital Market. Zhengye has 180 calendar days until November 25 to regain compliance by achieving a closing bid price of at

Form 6-K Zhengye Biotechnology For: Jun 04

Thu, 04 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260604/26605571.html

Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Thu, 04 Jun 2026 16:05:00 -0400

Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, announced that the Company had received a written notification letter (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on May 29, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules 5550(a)(2) for continued listing on the Nasdaq.

Nasdaq Listing

Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Thu, 04 Jun 2026 16:05:00 -0400

Nasdaq Listing

Form 20-F Zhengye Biotechnology For: Dec 31

Tue, 28 Apr 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260428/26384686.html

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

Tue, 28 Apr 2026 16:30:00 -0400

JILIN, China, April 28, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced its financial results for the fiscal year ended December 31, 2025.

Mr. Songlin Song, co-chief executive officer of Zhengye, remarked, "Fiscal year 2025 was a year of resilience for Zhengye. While the broader hog market experienced low and volatile price fluctuations and government macro-control policies contributed to near-term

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

Tue, 28 Apr 2026 16:30:00 -0400

Form 3 Zhengye Biotechnology For: Mar 24 Filed by: Li Guohan (nmn)

Fri, 24 Apr 2026 18:39:00 -0400

si-local-file:///var/storage/secattach/20260424/26367713.html